Asia
It was an unusually busy week for clinical trial updates, largely because of the annual ASH meeting from Sunday December 5 through Wednesday December 9. There were also other meetings and the usual corporate updates.
AstraZeneca, which is jointly developing a COVID-19 vaccine with the University of Oxford, plans to begin clinical trials testing its vaccine in combination with Russia’s Sputnik V vaccine by the end of the year.
Viruses mutate, and SARS-CoV-2, the virus that causes COVID-19, is not different. Luckily, it appears to mutate relatively slowly. Meanwhile, researchers are beginning to get a grip on the virus’s evolution.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The COVID-19 vaccine under development by China’s Sinopharm is showing efficacy of 86%, health authorities from the United Arab Emirates reported this morning.
SciNeuro Pharmaceuticals, based in Shanghai, China, launched with a $100 million Series A financing.
Governments across the globe have flexed their financial muscles to secure promises of as many doses of COVID-19 vaccines as possible when they become available.
Has China found a super-soldier formula through the capabilities of genetic engineering? A U.S. govt. official claims, China Super Soldiers are under development.
As if attempting to steal hard-won research wasn’t bad enough, hackers are now hitting people where it really hurts – with e-documents containing malicious code embedded in false offers of employment.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
PRESS RELEASES